tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther. 2015 Feb;13(2):197-207. doi: 10.1586/14787210.2015.999668.
[h=1]Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.[/h] Chung DR[SUP]1[/SUP], Huh K.
[h=3]Author information[/h]
[h=3]Abstract[/h] Postinfluenza bacterial pneumonia is a leading cause of influenza-associated death, and Staphylococcus aureus and Streptococcus pneumoniae have been important pathogens that have caused pneumonia since the influenza pandemic in 1919. Emergence of novel influenza A (H1N1) pdm09 and the concomitant global spread of community-associated methicillin-resistant S. aureus (CA-MRSA) have led to increasing prevalence of CA-MRSA pneumonia following influenza infection. Such an epidemiologic change poses a therapeutic challenge due to a high risk of inappropriate empiric antimicrobial therapy and poor clinical outcomes. Early diagnosis and initiation of appropriate antimicrobial therapy for post-influenza bacterial pneumonia have become even more important in the era of CA-MRSA. Therefore, novel molecular diagnostic techniques should be applied to more readily diagnose MRSA pneumonia.
[h=4]KEYWORDS:[/h] anti-bacterial agents; bacterial drug resistance; bacterial pneumonia; coinfection; linezolid; vancomycin
PMID: 25578884 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25578884
[h=1]Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.[/h] Chung DR[SUP]1[/SUP], Huh K.
[h=3]Author information[/h]
[h=3]Abstract[/h] Postinfluenza bacterial pneumonia is a leading cause of influenza-associated death, and Staphylococcus aureus and Streptococcus pneumoniae have been important pathogens that have caused pneumonia since the influenza pandemic in 1919. Emergence of novel influenza A (H1N1) pdm09 and the concomitant global spread of community-associated methicillin-resistant S. aureus (CA-MRSA) have led to increasing prevalence of CA-MRSA pneumonia following influenza infection. Such an epidemiologic change poses a therapeutic challenge due to a high risk of inappropriate empiric antimicrobial therapy and poor clinical outcomes. Early diagnosis and initiation of appropriate antimicrobial therapy for post-influenza bacterial pneumonia have become even more important in the era of CA-MRSA. Therefore, novel molecular diagnostic techniques should be applied to more readily diagnose MRSA pneumonia.
[h=4]KEYWORDS:[/h] anti-bacterial agents; bacterial drug resistance; bacterial pneumonia; coinfection; linezolid; vancomycin
PMID: 25578884 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25578884